Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-14-059634
Filing Date
2014-09-24
Accepted
2014-09-24 17:42:58
Documents
1
Period of Report
2014-09-22

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 15761
  Complete submission text file 0001209191-14-059634.txt   17959
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-36620 | Film No.: 141119113
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Reporting) CIK: 0001297709 (see all company filings)

State of Incorp.: D0 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-36620 | Film No.: 141119114

Mailing Address 1 Broadway 14TH FLOOR Cambridge MA 02142
Business Address 1 Broadway 14TH FLOOR Cambridge MA 02142 617-225-4348
Tokai Pharmaceuticals Inc (Issuer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations